Obesity

Background: Early postoperative weight loss may help predict later outcomes, but its reliability for longer-term weight loss and regain remains unclear. We assessed whether the percentage total weight loss (%TWL) 3 months after metabolic/bariatric surgery predicted later %TWL weight change/regain. Methods: This retrospective observational cohort study included 216 patients from a prospectively pre-recruited multicentre bariatric surgery cohort who underwent sleeve gastrectomy or Roux-en-Y gastric bypass and had 3-month %TWL and at least one later outcome. Linear regression assessed associations between 3-month %TWL and later %TWL plus weight change/regain outcomes. Adjusted incremental R2 quantified the additional variance explained by 3-month %TWL. Secondary procedure-stratified, diabetes-stratified, and baseline BMI comparator analyses are reported in the Supplementary Material. Results: Greater 3-month %TWL was associated with higher 1-year and 2-year %TWL in adjusted models (both p < 0.001) but not longer-term %TWL (p = 0.078). Incremental R2 was 38.23% for 1-year, 11.75% for 2-year %TWL and 2.25% for long-term %TWL. Greater 3-month %TWL was also associated with greater recurrent weight gain from 1 to 2 years and from 1 year to long-term follow-up. In secondary analyses, findings were broadly consistent across procedure and diabetes subgroups, while 3-month %TWL explained more additional variance in 1-year %TWL than baseline BMI Conclusion: 3-month %TWL predicted 1-year and 2-year outcomes but not longer-term %TWL, supporting its value as an early marker of postoperative weight trajectory. Heterogeneity in recurrent weight stability may contribute to weaker long-term prediction and warrants further study to determine whether early weight-loss patterns can identify patients requiring closer long-term weight management support.

Background & Aims: Childhood obesity is a complex, heterogeneous disease. Children with obesity are often grouped into metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) phenotypes, although this classification may oversimplify the underlying metabolic diversity. We aimed to characterise the metabolic profiles associated with the conventional MHO/MUO classification and to identify data-driven metabolic profiles in 267 children and adolescents with obesity. Methods: In this cross-sectional study, we used serum 1H-NMR spectroscopy to quantify lipoproteins, glycoproteins, low-molecular-weight metabolites, and lipid fractions. Univariate comparisons and partial least squares discriminant analysis (PLS-DA) were used to characterise NMR-derived variables associated with MHO and MUO groups. We applied unsupervised k-means clustering based on principal component scores to identify data-driven metabolic profiles independent of the predefined clinical phenotypes. Results: Forty-one NMR-derived variables differed between MUO and MHO (FDR q-value < 0.05), predominantly in the triglyceride-rich lipoprotein and glycoprotein profiles, of which 31 were elevated in MUO. PLS-DA discriminated between MHO and MUO (AUC = 0.84, Q2 = 0.33; permutation p < 0.001). Unsupervised clustering identified two data-driven metabotypes that only partially overlapped with the clinical phenotypes: 27% of children with MHO clustered within the adverse metabolic profile (Cluster 2), characterised by a triglyceride-rich and inflammation-associated profile, whereas 41% of children with MUO were assigned to the comparatively favourable profile (Cluster 1). Clustering further revealed additional differences in lipoprotein subclasses and lipid composition that the MHO/MUO classification did not capture. Conclusions: The conventional MHO/MUO classification captures an important component of metabolic variation in childhood obesity but does not fully capture cardiometabolic heterogeneity. Quantitative 1H-NMR metabolomics identified putative metabotypes characterised by differences in lipoprotein composition and cholesterol distribution beyond clinical phenotypes. These findings support the potential value of metabolomic profiling to refine cardiometabolic risk stratification in children with obesity; however, the relevance of these data-driven metabotypes requires confirmation in independent cohorts and longitudinal follow-up studies.

Background: Real-world evidence on food-as-medicine programs for irritable bowel syndrome (IBS) is scarce, and single-arm evaluations overstate improvement because of regression to the mean (RTM). We estimated change in the IBS Symptom Severity Scale (IBS-SSS, 0-500) in a multi-omics personalized digital health food-as-medicine program, unadjusted and RTM-corrected. Methods: Retrospective single-arm cohort. Of 15,933 members with a valid baseline, 2,254 had a follow-up reading and 1,683 one at least 14 days after baseline. Change at 4, 12 (primary) and 26 weeks was estimated by baseline severity stratum, unadjusted and RTM-corrected by analysis of covariance. A responder fell by at least 50 points (the minimal clinically important difference benchmark). Sensitivity analyses covered equity, inverse-probability weighting and tipping-point analyses for members without a reading in each landmark window, a negative-control stratum and medication. The association of weight loss and dietary nutrient density with symptom change was evaluated within and between members. Results: At 12 weeks (n = 430) IBS-SSS fell by 43.88 points unadjusted (95% confidence interval [CI] -52.44 to -35.32; p < 0.001) and by 47.73 RTM-corrected (-55.48 to -39.98; p < 0.001); 720 of 1,339 symptomatic members (53.8%; 95% CI 51.1 to 56.4) fell by at least 50 points. Larger improvement in more severe members persisted after RTM correction (severe stratum, n = 37: unadjusted -127.43, RTM-corrected -60.71, 95% CI -97.75 to -23.68, p = 0.001). A higher meal nutrient density was associated with lower IBS-SSS within a member's own trajectory (p = 0.018) while weight change was not (p = 0.361). Improvement was similar across groups in spite of baseline differences by age and sex: RTM-corrected 12-week change did not differ by age (p = 0.458), body-mass index (p = 0.328), sex (p = 0.749), income (p = 0.486) or ethnicity (p = 0.170). Estimates were robust to weighting for members without a reading in the landmark window (RTM-corrected estimates moved by less than 2 points), and the change of those members would have had to be 39 to 73 points worse than observed before the mean change reached zero. Baseline medication use and starting a GLP-1 receptor agonist did not explain symptom changes. Conclusions: IBS-SSS fell significantly among program participants, with steeper improvement in the more severe group, even after RTM correction. The improvement was comparable across socioeconomic characteristics, age and sex and robust to the confounders and missing-data assumptions evaluated. These associations from a self-selected single-arm cohort warrant replication in independent studies.

Purpose: In high-income countries, lower socioeconomic position (SEP) is linked to higher childhood obesity prevalence but its association with cardiometabolic risk in those presenting in pediatric weight management services remain underexplored. Methods: In the Bern Obesity in Childhood and Adolescence Biorepository (BOCAB), we used the Swiss neighborhood index of SEP (0-100, 100=highest SEP) to assess cross-sectional associations with obesity severity and cardiometabolic risk factors, mediation by behavioral lifestyle factors and longitudinal associations between SEP and percentage of the 95th BMI percentile (%BMIp95) and waist circumference-to-height ratio (WHtR), adjusted for age and sex. Results: Among 886 participants (52% male, mean age 11.2 years [SD 3.1]), mean %BMIp95 was 124% (SD 17%). A 10-unit higher SEP was associated with lower %BMIp95 ({beta} -2.57; 95% CI -3.84 to -1.31) and lower WHtR ({beta} -0.006; -0.010 to -0.001), both partially mediated by weekly physical activity and screen time. Higher SEP was also associated with lower odds of insulin resistance (OR 0.80; 0.65 to 0.98), low HDL-cholesterol (OR 0.81; 0.67 to 0.98), elevated non-HDL-cholesterol (OR 0.74; 0.59 to 0.92) and elevated triglycerides (OR 0.83; 0.70 to 0.98). Among 419 participants with longitudinal data, annual reduction in %BMIp95 and WHtR did not differ by SEP. Conclusion: Lower SEP is associated with greater obesity severity and cardiometabolic risk among children and adolescents with obesity presenting at specialized tertiary care. Screening and early referral of lower-SEP children and adolescents with obesity should be encouraged, before cardiometabolic risk accumulates, particularly since treatment response did not differ once enrolled.

Background: Both fetal and maternal genomes contribute to birthweight, but the timing and relative magnitude of their effects during gestation remain unclear. Polygenic risk scores (PRSs), constructed from genome-wide association studies (GWAS), capture the cumulative influence of common birthweight-associated variants to quantify genetic predisposition to fetal growth. We constructed fetal and maternal PRSs for birthweight in two UK birth cohorts, the Pregnancy Outcome Prediction Study (POPS) and Born in Bradford (BiB), to evaluate their associations with estimated fetal weight (EFW) throughout pregnancy and with birthweight at delivery. We also investigated whether PRSs could improve risk stratification of infants born below the 10th centile by distinguishing those with pathological intrauterine growth restriction (IUGR) from those who are constitutionally small-for-gestational-age (SGA). Methods: In POPS and BiB, we used LDpred2-auto to estimate PRSs based on the largest available maternal and fetal GWAS for birthweight. We longitudinally assessed EFW associations with PRSs using linear mixed effects models in POPS and BiB. We evaluated birthweight associations with PRSs using linear models, where birthweight was adjusted for gestational age and fetal sex. We estimated R2 and conducted variance decomposition analyses for all models. Genetically-predicted birthweights were estimated from joint models of fetal and maternal PRSs plus ten genetic principal components (PCs). BiB analyses were conducted separately for genetically-inferred European (EUR) and South Asian (SAS) ancestry. Results: While PRSfetus was significantly associated with EFW at baseline ([~]22 weeks gestation) across cohorts, PRSmother was not. Both the interaction of PRSfetus and PRSmother with gestational age (GA) were significantly associated with EFW. The effect of PRSmother on EFW increased more quickly across gestation than the effect of PRSfetus in POPS, but this finding was not replicated in BiB. Jointly, fetal and maternal polygenic risk explained 4% of variance in EFW in POPS and 1% in BiB-EUR. In POPS, fetal and maternal PRSs showed independent contributions to EFW variance of 3% and 0.5%, respectively. Joint and univariable linear models showed significant positive associations of PRSfetus and PRSmother with observed birthweight. In POPS, PRSfetus and PRSmother accounted for [~]10% and [~]4% of variance in birthweight over covariates alone, respectively, which was replicated in BiB-EUR. Maternal and fetal genetic effects jointly explained 11% of birthweight variance in POPS, similar to BiB-EUR, at 12%; however, the variance explained was reduced by half in BiB-SAS, at 6%. Among POPS babies born <10th birthweight centile, the magnitude of the difference between observed and genetically-predicted birthweight was greater in the group judged clinically to be IUGR vs. SGA (p=0.008; point estimate=0.29, 95%CI: 0.12, 0.47). Conclusions: Maternal and fetal PRSs jointly account for [~]11-12% of birthweight variance in European ancestry groups, but much less in a South Asian cohort. In POPS, the effect of birthweight-associated SNPs on estimated fetal weight increases more rapidly across pregnancy for maternal than for fetal genetic effects. Deviation from genetically-predicted birthweight may be a useful metric to help distinguish growth-restricted from constitutionally small babies.

Postmenopausal women are vulnerable to metabolic dysfunction. Compelling evidence suggests this is because they lack the protective effects of estrogens. We have shown that circulating estrogens regulate daily eating and activity rhythms in female mice and protect them from obesity and metabolic dysfunction. However, few studies have investigated whether postmenopausal women have disrupted eating and sleep-activity rhythms that could contribute to metabolic dysfunction. The purpose of this cross-sectional study was to investigate the relationship between sleep and eating rhythms and metabolic risk in postmenopausal women with overweight or obesity. Seven days of sleep and food intake behavior data were collected from postmenopausal women with overweight or obesity. Sleep timing was assessed using wrist-worn actigraphy and sleep logs. First and last calorie intake times were collected daily using text messaging. Visceral adipose tissue (DXA), insulin resistance (Matsuda index), blood pressure, and triglycerides were analyzed as markers of metabolic risk. In 122 postmenopausal women (mean {+/-} SD: 58.1 {+/-} 3.6 yr, 33.2 {+/-} 5.2 kg/m2 BMI), we found that later sleep onset was associated with greater visceral adipose tissue (p=0.0007), but not insulin resistance, blood pressure, or triglycerides. Next, we used a random forest model to quantify the relative contributions of sleep and meal timing variables to predict visceral adipose tissue. The top predictors of visceral adipose tissue were time of sleep onset, sleep duration, and time of last caloric intake. These data suggest that interventions that advance sleep onset may reduce metabolic risk in postmenopausal women.

Introduction: Adipose tissue fibrosis has been associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and suboptimal weight loss after bariatric surgery. The objective was to characterize changes in adipose tissue fibrosis and extracellular matrix (ECM) components in adipose tissues from two abdominal fat compartments, subcutaneous and omental, in response to bariatric surgery; and determine the effect of weight loss on the association between adipose tissue fibrosis and MASLD feature changes with weight loss. Methods: Liver and adipose tissue biopsy samples were obtained before and after weight loss from patients who underwent two-stage bariatric surgery. Adipose tissue pericellular fibrosis was evaluated histologically with picrosirius red staining for collagen quantification and normalized to adipocyte count per microscope field. Transcript levels of ECM remodeling and inflammatory genes were measured by RNA sequencing in subcutaneous adipose tissue pre- and post-surgery. Results: At baseline, adipose tissue pericellular fibrosis did not associate with MASLD features, metabolic dysfunction-associated steatohepatitis or hepatic fibrosis in patients with severe obesity. Changes in liver histology after surgery were unrelated to changes in adipose tissue fibrosis. Transcripts for most genes involved in ECM remodeling and inflammation were downregulated in subcutaneous fat one year after bariatric surgery. Omental, but not subcutaneous, adipose tissue fibrosis decreased after surgery when adjusted for cell number (mean {+/-} SD: 0.41 {+/-} 0.12 vs 0.32 {+/-} 0.08 {micro}m2/cell, p<0.005). Higher subcutaneous adipose tissue fibrosis correlated with reduced weight loss (estimate {+/-} SE: -2.04 {+/-} 0.99, p<0.05) and BMI loss (-0.73 {+/-} 0.35, p<0.05), while increased omental adipose tissue fibrosis after weight loss was associated with worsening hepatic fibrosis (0.31 {+/-} 0.14, p<0.05). Conclusion: In individuals with severe obesity undergoing bariatric surgery, adipose tissue fibrosis is poorly correlated with MASLD features. Notably, pericellular fibrosis in subcutaneous abdominal, but not omental, adipose tissue was associated with a reduced weight-loss response to surgery.

Background: Intramuscular fat and fibrous tissue deposition increase with ageing, disuse, and disease and contribute to impaired muscle function and reduced 'muscle quality'. Magnetic resonance imaging (MRI) and biopsy provide reference measures of muscle composition, but their cost, invasiveness, and limited accessibility restrict routine use. B-mode ultrasonography has emerged as a practical, low-cost alternative, with ultrasound-derived echo intensity widely interpreted as a surrogate measure (index) of intramuscular fat, fibrosis, and 'muscle quality'. However, such interpretation warrants further scrutiny. Aim: To quantify the relationship between ultrasound-derived echo intensity and reference measures of intramuscular fat and fibrous tissue and determine whether these relationships vary across muscles or according to anatomical and methodological factors. Methods: A systematic search of six databases was conducted (last search: August 2026). Human and animal studies reporting correlations between echo intensity and measures of intramuscular fat or fibrous tissue using MRI, histology, or chemical analysis were synthesised using multilevel random-effects meta-analysis with study-level cluster-robust inference. Correlations were Fisher z-transformed and back-transformed for interpretation. Exploratory analyses examined fat compartment, muscle, muscle architecture, health status, study model, and distance-correction procedures. Results: Twenty-eight studies met the eligibility criteria. For intramuscular fat, 204 effects from 23 independent studies yielded a weak-to-moderate pooled correlation with echo intensity (r=0.54, 95% CI: 0.45-0.61; 95% PI: - 0.02-0.84; P<0.01), with substantial heterogeneity (I^2=74.5%). The wide prediction interval suggests the true correlation could range from negligible to strong. No significant moderation effects were observed for study model (animal vs. human: r=0.46 vs. 0.55; P=0.26), health status (clinical vs. healthy: r=0.64 vs. 0.49; P=0.11), probe-to-muscle distance correction (corrected vs. raw echo intensity: r=0.57 vs. 0.53; P=0.25), or muscle architecture (non-pennate vs. pennate: r=0.63 vs. 0.53; P=0.56), although some categories contained few studies and effects. Model-based inference indicated significant moderation effect of lipid compartment (intramyocellular lipid vs. total intramuscular fat vs. extramyocellular lipid: r=0.10 vs. 0.57 vs. 0.49; P<0.001) but this effect was not significant under cluster-robust inference (P=0.50). For fibrous tissue, six effects from four studies yielded a weak, non-significant pooled correlation (r=0.34, 95% CI -0.39, 0.81], 95% PI [-0.85, 0.96]; P=0.24). Conclusions: Echo intensity is weakly-to-moderately associated with intramuscular fat, and this varied substantially across studies and muscles, whereas evidence for intramuscular fibrous tissue is limited and uncertain. These findings provide limited support for interpreting echo intensity as a surrogate measure or an index of intramuscular fat or fibrosis or, on this basis, as an index of 'muscle quality'.

Glucagon-like peptide-1 (GLP-1) receptor agonists produce less weight loss in people with type 2 diabetes than without, and higher compensatory doses are limited by gastrointestinal adverse events and lean-mass loss--leaving patients with obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH) inadequately treated. We tested whether linafexor, a pulsatile farnesoid X receptor (FXR) agonist, could augment the weight-loss efficacy of low-dose semaglutide in this population while preserving tolerability. In this multicenter, randomized, double-blind, placebo-controlled, phase 2 trial, 62 adults with obesity (body-mass index, 30-45 kg/m2), treatment-naive type 2 diabetes, and MASH (MRI-PDFF [&ge;]10%) were assigned to linafexor (4 mg orally once daily) or placebo, each with semaglutide (0.5 mg once weekly), for 16 weeks. The primary outcome was the percentage change in body weight at week 16. Adding linafexor more than doubled weight loss (-6.17% vs. -2.91%; treatment difference, -3.26%; 95% CI, -5.35 to -1.18; P=0.003), and more participants achieved at least 5% weight loss (53.3% vs. 28.1%; P=0.046). Consistent with this, combination therapy further reduced visceral adipose tissue (treatment difference, -13.85 cm2; P=0.035), the liver enzymes alanine aminotransferase and {gamma}-glutamyl transferase, and serum bile acids, whose changes correlated with weight and liver-enzyme improvements--associations absent with monotherapy. Gastrointestinal adverse events were comparable (23.3% vs. 18.8%), with no treatment-related serious adverse events or discontinuations. Thus, in a population with blunted GLP-1 responses, adding linafexor to low-dose semaglutide enhanced weight loss and improved body composition and hepatic measures while preserving tolerability--a dose-sparing, mechanism-complementary strategy (ClinicalTrials.gov number, NCT06492330).

Obesity and metabolic diseases such as diabetes reflect long-term interactions between diet, lifestyle, and genetics, variables that are hard to control in humans but can be systematically varied in mice, though behavioral variables like long-term exercise remain harder to model. Having previously phenotyped ~50 BXD strains, we identified BXD40, BXD43, and BXD100 as predisposed to voluntary wheel-running (~6 km/day at 24 weeks) with variable susceptibility to diet-induced obesity and diabetes. We followed these strains from 8-32 weeks on a 60% kcal/fat high-fat (HF) diet, with or without access to running wheels. Wheel usage declined from ~9 km/day in the first two weeks to a steady ~5 km/day thereafter yet still improved oral glucose tolerance by 35% over sedentary controls by 24 weeks. Despite equivalent body weight, runners ate 20% more relative to body weight, indicating the glucose benefit was independent of caloric intake. We next asked whether the gut microbiome contributes to this benefit. Long-term exercise produced only modest, cohort-dependent shifts in cecal microbial composition, though functional profiling revealed exercise-associated differences in carbohydrate- and glucose-metabolism pathways. Reciprocal bedding exchange between sedentary and running BXD43 cages reduced microbial differentiation in a taxon-specific manner and coincided with marked attenuation of the glucose phenotype, despite unchanged running behavior. Together, these findings validate BXD40, BXD43, and BXD100, alongside the canonical C57BL/6, as a model for studying diet, exercise, and genetics in metabolic disease, and implicate gut microbial taxa in shaping exercise's metabolic effects during HF feeding.

The post-ingestive dopamine response is an integral determinant of subsequent eating behavior in animals yet measurement of the post-ingestive response to nutrients in humans has been elusive when assessed in the early post-ingestive period (30 minutes postprandially). We conducted secondary analysis comparing dopamine D2 receptor binding potential (D2BP) measured using [18F]fallypride positron emission tomography in two inpatient controlled feeding cohorts consuming standardized diet (50% carbohydrate; 35% fat; 15% protein) with similar characteristics and procedures but differing in time since last meal: confirmed overnight fast (n=57; 66.7% female; BMI 29.6{+/-}7.6 kg/m2; 31.9{+/-}7.2 years old) and 2-hours after a standardized meal reflecting 20% of energy requirements (n=43; 48.8% female; BMI 28.8{+/-}7.8 kg/m2, 31.3{+/-}7.7 years old). Compared to the fasted cohort, the 2-hour postprandial cohort exhibited significantly reduced whole striatal D2BP (p<0.0001) as well as in clusters in insular cortex, prefrontal cortex which remained after adjustment for age, sex, and insulin sensitivity. Voxelwise comparisons of the relationship between D2BP and BMI in the fasted and fed cohorts reveals clusters within dorsolateral and ventral striatum where dopamine level is dependent on postprandial state and adiposity. Given the similarities between protocol procedures and participant characteristics, our results suggest that the post-ingestive dopamine response to nutrients may be prominent in the extended post-ingestive period and warrant investigation within-subject.

Background The consequences of prolonged exposure to obesity on biomarkers of myocardial stress and injury remain unclear. We examined associations of duration and cumulative severity of obesity from childhood to later adulthood with concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin I (hs-cTnI), and growth differentiation factor-15 (GDF-15) at age 62 years. Methods The sample comprised 4,901 participants in the 1958 National Child Development Study who had measurements of NT-proBNP, hs-cTnI, or GDF-15 at age 62 years and at least four BMI assessments between 7 and 62 years of age. Individual BMI trajectories were modelled, from which total duration of obesity and mean excess BMI (area between the trajectory and the age-specific obesity threshold divided by duration) were derived. Associations of ever versus never having been obese, obesity duration, and mean excess BMI with biomarker concentrations were examined using general linear regression models with progressive adjustment for early-life characteristics; contemporaneous cardiometabolic factors; and health behaviours, socioeconomic position, and psychosocial factors. Nonlinear associations of obesity duration were estimated using restricted cubic splines and subsequently approximated using linear splines. Results Overall, 26.3% of participants had ever experienced obesity. There was no evidence of an association between ever versus never having been obese and NT-proBNP. Among men, ever having been obese was associated with 11.00% (95% CI, 4.62-17.37) higher hs-cTnI in the fully adjusted model, whereas there was no evidence of an association among women. Ever having been obese was associated with higher GDF-15, although the association attenuated substantially after adjustment for contemporaneous cardiometabolic factors. Longer obesity duration was associated with higher concentrations of all three biomarkers in fully adjusted models, but the pattern differed by biomarker: hs-cTnI increased approximately linearly with duration, whereas NT-proBNP and GDF-15 remained relatively stable up to approximately 25 years of obesity before increasing with longer duration. In fully adjusted models, each additional year of obesity beyond 25 years was associated with 1.80% (95% CI, 0.54-3.06) higher NT-proBNP and 0.81% (95% CI, 0.25-1.36) higher GDF-15, while each additional year across the full range of obesity duration was associated with 0.41% (95% CI, 0.07-0.76) higher hs-cTnI. Among participants who had ever experienced obesity, each 1 kg/m2 higher mean excess BMI was associated with 4.02% (95% CI, 1.79-6.24) higher NT-proBNP and 2.00% (95% CI, 0.49-3.51) higher hs-cTnI in fully adjusted models; there was no evidence of an association with GDF-15. Conclusions Longer duration of obesity was associated with higher concentrations of biomarkers reflecting myocardial stress, injury, and cellular stress at age 62 years, with associations particularly evident after approximately 25 years of obesity for NT-proBNP and GDF-15. These findings suggest that duration of obesity may provide clinically relevant information beyond current obesity status, supporting its consideration as an additional dimension of cumulative obesity burden in cardiovascular risk assessment.

Background: Circadian syndrome (CircS) comprises metabolic abnormalities, short sleep, and depressive symptoms, and is associated with cardiovascular, liver, and lung diseases and mortality; evidence on digestive disease is scarce. We assessed its association with incident non-neoplastic digestive disease in Chinese adults. Methods: In this prospective analysis of the China Health and Retirement Longitudinal Study (CHARLS), we included 2011 baseline participants aged >=45 years free of digestive disease, with follow-up to 2018. CircS (>=4 of 7 components) was analysed as a continuous score and as a binary exposure. Cox models estimated hazard ratios (HRs) adjusting for demographic factors, BMI, smoking, and alcohol use. We did dose-response, component, subgroup, and sensitivity analyses; hs-CRP mediation was explored. Findings: 907 (19.0%) of 4 771 participants developed digestive disease over a median 84 months. Each additional CircS component raised the risk by 9.1% (HR 1.091, 95% CI 1.041-1.144, P<0.001); CircS positivity (36.1%) was associated with a 25.7% higher risk (HR 1.257, 1.084-1.456, P=0.002). Risk rose approximately linearly to about 70% higher at 5-7 components. Short sleep (HR 1.178, 1.017-1.365) and depressive symptoms (HR 1.570, 1.367-1.803) were the only independently associated components; no metabolic component was associated. Results were robust across sensitivity analyses; hs-CRP did not mediate the association. Interpretation: CircS is associated with incident non-neoplastic digestive disease, driven by its circadian-emotional rather than metabolic components. Sleep and mood may be targets for prevention. Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Keywords: circadian syndrome; digestive diseases; cohort study; sleep; depression; brain-gut axis

Background: Thinness-oriented body ideals are well described among young Japanese women, but variation in visual and numerical ideals by sex, age, and current BMI remains unclear. Methods: We analysed an unweighted web-panel sample of 27,359 Japanese adolescents and adults aged 15-69 years from the Survey of Body Shape and Health Awareness in Japanese People, a cross-sectional web-based survey. Current and ideal BMI were derived from self-reported height and weight, and visual orientation from ideal versus perceived current silhouette. Adult BMI-stratified analyses included participants aged 20-69 years. Findings: Among 27,359 participants (10,094 men and 17,265 women), relative thinness-oriented indicators increased with current BMI in both sexes. Among normal-weight women, 74.7-83.7% selected a smaller ideal silhouette and 79.2-91.2% reported an ideal BMI lower than current BMI. These indicators were also present among underweight women aged 20-29 years (44.9% and 43.4%, respectively), but declined with age. Most underweight men reported weight-gain-oriented ideals. Fine stratification showed that thinness-oriented ideals among women were common in low-normal and mid-normal BMI strata. Interpretation: Body-size ideals differed by sex, age, and current BMI. Thinness-oriented ideals among women extended beyond obesity and young adulthood, whereas underweight men generally preferred a larger body. Longitudinal and behavioural studies are needed. Funding: Cabinet Office of Japan Strategic Innovation Promotion Program (SIP), "Inclusive Community Platform" (grant no. SIPCP23C02).

Abstract Background: Randomized trials show substantial weight loss with semaglutide and tirzepatide under structured care, but little is known about whether patients in routine practice continue therapy, reach a maintenance dose, and have their weight measured. Objectives: To describe the first year after initiation of semaglutide or tirzepatide for obesity, including care patterns, maintenance-dose attainment, weight documentation, and total body weight loss (TBWL). Methods: This retrospective cohort study used Epic Cosmos, an electronic health record network of >350 US health systems, to identify adults with obesity and without diabetes who initiated injectable semaglutide or tirzepatide in 2024. Outcomes over 12 months included prescribing persistence, discontinuation, switching, add-on therapy, and reinitiation; attainment of Food and Drug Administration (FDA)-labeled maintenance doses; availability of follow-up weight; and TBWL across progressively restricted populations. Results: Among 743,153 adults (60.1% semaglutide; mean age, 48.5 years; 72.5% female), 12-month prescribing persistence was 29.9% for semaglutide and 35.9% for tirzepatide. FDA-labeled maintenance-dose attainment was 28.3% and 55.0%, respectively, and only 8.8% and 16.4% remained prescribing persistent at a maintenance dose with a recorded weight at 12 months. About half of initiators lacked a 12-month weight. Among all initiators, [&ge;]5% TBWL was documented in 25.6% (semaglutide) and 30.4% (tirzepatide), rising to 51.9% and 61.9% among those with recorded weight, 66.1% and 79.5% among those also prescribing persistent, and 82.9% and 87.3% among those further at a maintenance dose. Conclusions: In routine practice, most patients initiating semaglutide or tirzepatide did not remain on therapy, reach a maintenance dose, and have weight documented through the first year. Documented weight loss was greatest among those completing each step of care, suggesting continuation, dose escalation, and monitoring as targets for improvement.

Objective: To study the prevalence of co-occurring endometriosis and polyendocrine metabolic ovarian syndrome (PMOS), estimate infertility odds, and characterize menstrual symptom profiles associated with this combined phenotype in a population cohort. Design: Prospective digital cohort in the United States (US). Subjects: 90,714 consented participants enrolled between November 2019 and June 2025 who completed relevant surveys; a subset of 25,152 participants with menstrual cycle logs linked to monthly surveys contributed to symptom analyses. Exposure: Participants were classified by self-reported physician diagnosis into four groups: endometriosis alone, PMOS alone, co-occurring endometriosis and PMOS (endometriosis+PMOS), or neither condition (reference group). Main Outcome Measures: (1) Odds of self-reported physician-diagnosed infertility (ever/never, cross-sectional), estimated using multivariable logistic regression adjusted for age, race/ethnicity, and subjective socioeconomic status; (2) number of adverse menstrual symptoms logged per cycle, assessed using negative binomial mixed-effects models adjusted for age, race/ethnicity, and hormonal contraceptive use. Results: Among 90,714 participants, the mean age was 35.1 years (standard deviation: 11.6) and the majority identified as non-Hispanic White (72%). Prevalence estimates were 11% for PMOS alone, 6% for endometriosis alone, and 2% for endometriosis+PMOS. Individuals with endometriosis+PMOS more frequently reported unemployment, low socioeconomic status, active smoking, poorer subjective health, early menarche, current irregular cycles, and a broad range of comorbidities. Infertility odds were highest for endometriosis+PMOS (odds ratio: 12.49 [95% confidence interval: 11.13-13.99]), followed by PMOS alone (6.12 [5.69-6.59]) and endometriosis alone (4.31 [3.93-4.72]), with the combined effect exceeding additive expectations (relative excess risk due to interaction: 3.05 [1.65-4.46]). Individuals with endometriosis+PMOS logged 11% more symptoms per cycle than those with neither condition (incidence rate ratio: 1.11 [1.04-1.19]) and had the highest odds of logging pelvic pain, fatigue, and sleep changes, among other symptoms. Conclusion: In this large US digital cohort, co-occurring endometriosis and PMOS affected 1 in 50 participants and was associated with markedly elevated infertility odds exceeding additive expectations, and a heightened menstrual symptom burden. Several risk factors and health impacts characteristic of each condition appeared amplified in individuals with both conditions, suggesting a subgroup with compounded clinical complexity and greater care needs.

Gestational diabetes mellitus (GDM) is associated with significant maternal and neonatal morbidity. Screening strategies vary internationally and the diagnostic performance of the 50g glucose challenge test (50g GCT) as a universal screening tool remains uncertain across diverse populations. This retrospective cohort study included 18,213 singleton pregnancies at a London tertiary hospital between 2010 and 2023. Women routinely underwent the universal two-step GDM screening pathway: a 50g GCT at 24 - 32 weeks' gestation, followed by a diagnostic 75-g oral glucose tolerance test if the 50g GCT result was greater than or equal to 7.8 mmol/L. We evaluated the use of universal two-step screening in detecting GDM, how its prevalence varies with maternal characteristics, including ethnicity, body mass index, age, and in those who would not have been included in risk factor-indicated screening, and the association between the 50g GCT and adverse outcomes. 2,015 women had an abnormal GCT, and 406 (20.1%) had an abnormal 75g OGTT, with GDM diagnosed at 24-28 weeks. We also found 87 women, despite a normal GCT and/or normal OGTT, developed late-onset GDM. The overall prevalence of GDM was 4.4% (810/18,213). Universal screening will therefore identify a significant number of GDM cases, notably including those in a low-risk cohort who would not have been screened using a risk factor-based approach. When we examined glucose as a continuous variable, there was an association between increasing 50g GCT values and adverse maternal and neonatal outcomes. Universal screening with a GCT is a feasible and safe approach and addresses a significant health disparity gap, in that women without risk factors are screened and may be diagnosed with GDM. Given the long-term cardiometabolic implications of GDM, pregnancy diagnosis is important to allow for longer-term targeting of cardiometabolic risk factors to improve long-term health screening for type 2 diabetes and obesity.

Synchrony between time-of-day and food intake is critical for maintaining homeostasis while desynchrony between these cues caused by repeated bouts of mistimed eating (ME) is profoundly disruptive to organismal health. However, it is unknown whether the same is true for a single bout of ME. While it is generally accepted that mammals recover quickly from acute alterations in feeding schedule and that chrono-disruption requires chronic, repeated changes, there have been no dedicated investigations of acute ME to suggest otherwise. Therefore, we exposed female and male C57Bl6/J mice to a single bout of ME or timed eating (TE) and continuously measured metabolic and behavioral responses for five days. A single bout of ME was sufficient to disrupt the daily rhythms of metabolic and behavioral outcomes for several days. Energy expenditure and wheel running activity were disrupted and light:dark variation in food intake and macronutrient utilization were altered for several days. Finally, ME changed the amount of time spent resting in for several days post-ME. The TE paradigm disrupted macronutrient utilization for two days but otherwise had no effect on metabolism or behavior. Our results demonstrate that one instance of ME alone has lasting impacts on daily rhythmicity and is an understudied source of circadian disruption.

Enhanced excitability of output neurons in the olfactory bulb (OB) has been linked to regulation of energy homeostasis. The mechanism by which the olfactory system can drive metabolic state while processing odor information remains elusive yet must depend upon integration and relay to the rest of the brain. Herein, we screened brain-wide neuronal ensembles that preferentially engaged during odor stimulation (referred to as ODORTRAP) utilizing FOSTRAP activity mapping. Mice were exposed to the odor isopropyl tiglate (IPT), a preferred ligand for the olfactory receptor 160, previously shown to be vulnerable to diet-induced obesity. Odor activation resulted in elevated labelling in the olfactory bulb (ODORTRAP) (p < 0.001), as well as in higher olfactory cortices including anterior olfactory nucleus, piriform cortex, and cortical amygdala (p < 0.05). Interestingly, IPT differentially recruited hypothalamic feeding areas, namely the arcuate (ARC), dorsomedial (DMH) and lateral (LH) hypothalamus (p < 0.001), while the ventromedial hypothalamic nucleus and the suprachiasmatic nucleus exhibited no change in ODORTRAP activity (p > 0.05). In mice that were maintained on moderately high-fat (MHF) diets, we discovered that obesity re-models the activation pattern across the brain. Obese mice exhibited loss of ODORTRAP activity in the ARC (p < 0.0001), whereas in the DMH and LH increased baseline activity that obscured any odor-linked neural activity. While IPT activated the nucleus accumbens and medial septum in control mice (p < 0.01), obese mice demonstrated no changes in ODORTRAP activity (p > 0.05). Our study identifies key brain regions linking chemosensation and metabolic state, specifically demonstrating alteration in activity in hypothalamic domains upon obesogenic diet.

Importance: Pediatric obesity affects 1 in 5 US children and has been linked to brain structural differences. Most evidence is cross-sectional and models body mass index (BMI) linearly, with metrics that compress severe obesity. Objective: To examine associations between brain structure and BMI for age across the weight spectrum and Centers for Disease Control and Prevention (CDC) weight status categories, distinguishing between and within person associations, and their age and sex moderation. Design, Setting, and Participants: Longitudinal cohort study of youth aged 8 to 10 years at baseline in the US community based Adolescent Brain Cognitive Development Study (4 waves, 2016 to 2025; ages 8 to 18 years). Exposures: Extended CDC BMI-for-age z-score, grouped by wave-mean z-score: underweight (<5th percentile, n=297), healthy weight (5th to <85th, n=7,452), overweight (85th to <95th, n=1,919), and obesity ([&ge;]95th, n=1,842). Main Outcomes and Measures: Cortical thickness (12 regions) and subcortical volume (7 regions) from T1 weighted magnetic resonance imaging (MRI), defined a priori. Results: Among 11,510 participants contributing 32,212 observations (mean [SD] age, 12.6 [2.5] years; 52.2% male), higher between person BMI for age z was associated with lower frontal and temporal thickness (6 regions) and larger subcortical volume (5 regions; all q < .001), but associations were nonlinear (17 of 19 regions). Youth with obesity had lower thickness than healthy weight youth in 8 frontal and temporal regions (largest, -0.21 SD; q < .001), with dorsal frontal differences decreasing across adolescence; underweight youth had smaller subcortical volumes. Higher BMI for age z was associated with larger subcortical volume (all 7 regions) within the healthy weight category and lower cortical thickness (11 of 12 regions; fusiform: {beta} = -0.27; q < .001) within the obesity category, steeper than in healthy weight youth in 10 regions, but not in overweight or underweight youth. Within person associations did not reproduce the obesity associations, reversed from negative at age 10 to positive at age 16, and were more negative in female than male participants. Conclusions and Relevance: Youth with obesity had lower cortical thickness than healthy weight peers, but associations between brain structure and BMI for age differed between CDC weight status groups, suggesting a complex relationship between adiposity and brain structure.